Systemic treatment of non-small cell lung cancer brain metastases

In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): gefitinib o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cedrych, Ida, Kruczała, Maksymilian A., Walasek, Tomasz, Jakubowicz, Jerzy, Blecharz, Paweł, Reinfuss, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2016
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371701/
https://www.ncbi.nlm.nih.gov/pubmed/28373815
http://dx.doi.org/10.5114/wo.2016.64593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371701/
https://www.ncbi.nlm.nih.gov/pubmed/28373815
http://dx.doi.org/10.5114/wo.2016.64593

Ejemplares similares